Halberd Files Additional Extracorporeal Patent Application: Treatment of Covid-19 By Exposure to Tuned Radio Frequency Waves
JACKSON CENTER, PA / ACCESSWIRE / November 8, 2021 / Halberd Corporation (OTC PINK:HALB) filed a non-provisional patent application for the extracorporeal treatment of Covid-19 through exposure to radio frequency waves. Previously, Halberd filed a provisional patent application on this treatment method. Halberd believes this treatment would be effective against all SARS-CoV-2 variants, and this application preserves Halberd’s intellectual property rights. Halberd works to continue to perfect this underlying extracorporeal treatment process on neurodegenerative diseases.
The continuous flow treatment process, similar to dialysis, introduces a proprietary SARS-CoV-2 antibody, developed by Halberd, conjoined to a gold coated iron nanoparticle into the blood as it is removed from the patient. The antibody is designed with an affinity for the SARS-CoV-2 disease antigen and binds to the antigen when they come in contact. This antigen-antibody-nanoparticle complex is then exposed to calibrated radio frequency waves, which cause the complex to heat up and destroy the SARS-CoV-2 antigen. After exposure to radio frequency, the neutralized antigen-antibody-metallic nanoparticle complex (debris) is then removed from the blood through any of various processes before the blood is returned to the patient.
William A. Hartman, Chairman, President & CEO of Halberd Corporation, stated, “The technology developed in support of this patent application has been key in our related work on developing treatments for Alzheimer’s Disease, PTSD, Chronic Traumatic Encephalopathy (CTE), Traumatic Brain Injury (TBI) and many other neurological diseases, as well as bacteriological (e.g., E.coli) and viral infections, particularly those which have developed antibiotic resistance. Halberd’s primary focus will remain on neurological diseases, but this patent is intended to enhance Halberd’s value in the overall scientific community.”
To get the latest news on Halberd’s exciting developments, subscribe by submitting this form.
For more information please contact:
William A. Hartman
About Halberd Corporation.
Halberd Corporation (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed sixteen provisional, utility or PCT patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.
Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives –
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.
The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.
The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.
We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.